News | Heart Valve Technology | October 02, 2017

Medtronic Announces Post-Market Study for CoreValve Evolut Pro System

Study designed to assess longer-term clinical performance of next-generation transcatheter aortic valve implantation (TAVI) system

Medtronic Announces Post-Market Study for CoreValve Evolut Pro System

October 2, 2017 — Medtronic recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in everyday clinical practice. Studying patients with severe symptomatic aortic stenosis at an intermediate, high or extreme risk for open-heart surgery, the FORWARD PRO Clinical Study will evaluate longer-term performance (out to five years) of the next-generation self-expanding transcatheter aortic valve implantation (TAVI) system, which was recently approved for commercial use in Europe and United States.

The Evolut Pro valve, built off the Evolut R platform, is designed with an outer tissue wrap to further advance valve sealing performance. The biocompatible porcine pericardial tissue wrap, in addition to other design elements, is incorporated to address the occurrence of blood leaking through the sides of the valve. The first-ever data for the Evolut Pro valve, presented at the 2017 American College of Cardiology Scientific Sessions (ACC.17), showed no moderate/severe paravalvular leak (0 percent), high rates of survival (98.3 percent) and a low rate of disabling stroke (1.7 percent) at 30 days.

The multi-center, prospective single-arm clinical study will enroll 600 patients across 35 sites in Europe and will evaluate safety, including all-cause mortality and all stroke at 30 days, and clinical performance, including valve hemodynamics and paravalvular regurgitation. Patients will be followed out to five years.

“We look forward to replicating the excellent clinical outcomes demonstrated by the Evolut Pro valve in a study designed to look at the valve’s longer-term real-world performance,” said Prof. Eberhard Grube, M.D., director of the Structural Heart Program at University Hospital in Bonn, Germany, and co-principal investigator of the FORWARD PRO Study. “The Evolut Pro has shown exceptional results for patients with severe aortic stenosis and we are excited to enroll our first patients into this rigorous study.”

Watch the VIDEO “TAVR Stands Equal to Surgical Valve Replacement,” an interview with Michael Reardon, M.D., from ACC.17.

For more information:

Related Content

Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Clinical Study | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init